This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Renal Diseases, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Brendan D. Curti, MD

JAMA. 2004;292:97-100.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancy and 90% to 95% of neoplasms arising from the kidney.¹ It is the sixth leading cause of cancer death in the United States.² Approximately 31 200 new cases of RCC were diagnosed in the United States in 2000 and more than 11 900 affected individuals died. This disease often presents with few symptoms but it can have diverse paraneoplastic manifestations. It displays relative resistance to radiation and chemotherapy, although there have been occasional durable responses to interleukin 2 (IL-2)–based immunotherapy. Recent insights into the genetic changes associated with RCC have provided new targets for therapy.

Clinical Presentation

Renal cell carcinoma is a challenging diagnosis. It often remains clinically occult for most of its course.The simultaneous presence of the classic clinical triad of flank pain, hematuria, and flank mass is uncommon (10%) and is indicative of advanced . . . [Full Text of this Article]

Genetic Factors

Histologic Findings

Treatment Modalities

Surgical Care

Surgery in Metastatic Disease

Biological Therapies

Treatments in Development

Radiation Therapy

Prognosis

Conclusions

Author Affiliation: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Ore.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Nephron-Sparing Surgery and Renal Cell Carcinoma
Jonathan C. Routh, Bradley C. Leibovich, Horst Zincke, and Micheal L. Blute
JAMA. 2004;292(14):1684.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Kidney Cancer
Janet M. Torpy, Cassio Lynm, and Richard M. Glass
JAMA. 2004;292(1):134.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy
Sourbier et al.
Cancer Res. 2007;67:11668-11676.
ABSTRACT | FULL TEXT  

Inflammatory Nodules Mimic Applicator Track Seeding After Percutaneous Ablation of Renal Tumors
Lokken et al.
Am. J. Roentgenol. 2007;189:845-848.
ABSTRACT | FULL TEXT  

Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B
Agouni et al.
Carcinogenesis 2007;28:1893-1901.
ABSTRACT | FULL TEXT  

Dietary Risk Factors for Kidney Cancer in Eastern and Central Europe
Hsu et al.
Am J Epidemiol 2007;166:62-70.
ABSTRACT | FULL TEXT  

B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival
Krambeck et al.
Proc. Natl. Acad. Sci. USA 2006;103:10391-10396.
ABSTRACT | FULL TEXT  

Sunitinib in patients with metastatic renal cell carcinoma.
Motzer et al.
JAMA 2006;295:2516-2524.
ABSTRACT | FULL TEXT  

Contemporary techniques and safety of cardiovascular procedures in the surgical management of renal cell carcinoma with tumor thrombus
Lubahn et al.
J. Thorac. Cardiovasc. Surg. 2006;131:1289-1295.
ABSTRACT | FULL TEXT  

Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients
Wierecky et al.
Cancer Res. 2006;66:5910-5918.
ABSTRACT | FULL TEXT  

The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy.
Sourbier et al.
Cancer Res. 2006;66:5130-5142.
ABSTRACT | FULL TEXT  

Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo
Talon et al.
Carcinogenesis 2006;27:73-83.
ABSTRACT | FULL TEXT  

Sternal resection and reconstruction after renal cell carcinoma metastatic to the sternum
Pyle et al.
J. Thorac. Cardiovasc. Surg. 2005;129:1177-1178.
FULL TEXT  

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
Thompson et al.
Proc. Natl. Acad. Sci. USA 2004;101:17174-17179.
ABSTRACT | FULL TEXT  

Nephron-Sparing Surgery and Renal Cell Carcinoma
Routh et al.
JAMA 2004;292:1684-1684.
FULL TEXT